Myotonic Dystrophy 1
43
11
13
20
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 43 trials
100.0%
+13.5% vs benchmark
9%
4 trials in Phase 3/4
10%
2 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (43)
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
Study of ATX-01 in Participants With DM1
The Spanish National Registry for Myotonic Dystrophy Type 1
Global Study of Del-desiran for the Treatment of DM1
Calcium Channel Blocker in Myotonic Dystrophy Type 1
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China
Venous Thromboembolism in Myotonic Dystrophy Type 1
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Myotonic Dystrophy - Vascular and Cognition